Physician profile
Matthew Ryan Mcbride
NPI 1639731094
$2,150.81
in general payments reported to CMS, 2019-2025
15 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $382 · 2022: $309 · 2023: $413 · 2024: $656 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,460.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $486.62 | 2021-2025 | Total30, Dailies, Precision7 |
| Tarsus Pharmaceuticals, INC. | $480.29 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $301.46 | 2022-2025 | Xiidra, Miebo, Infuse |
| Lkc Technologies, INC. | $270.56 | 2023-2024 | |
| Biotissue Holdings INC. | $165.93 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $115.13 | 2021 | |
| Novartis Pharmaceuticals Corporation | $92.57 | 2022-2023 | |
| Johnson & Johnson Vision Care, INC. | $51.20 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $41.99 | 2022-2023 | Cequa |
| Abbvie INC. | $33.50 | 2022 | |
| Coopervision INC. | $31.18 | 2025 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.78 | 2021 | |
| Astellas Pharma Global Development | $20.90 | 2024 | Izervay |
| Allergan, INC. | $16.47 | 2022 | |
| Sight Sciences, INC. | $14.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.